Reverse genetics in Candida albicans predicts ARF cycling is essential for drug resistance and virulence

PLoS Pathogens

Volumn 6, Issue 2, 2010, Pages

  Epp, Elias ^a,b   Vanier, Ghyslaine ^b   Harcus, Doreen ^a   Lee, Anna Y ^c   Jansen, Gregor ^b   Hallett, Michael ^c   Sheppard, Don C ^b   Thomas, David Y ^b   Munro, Carol A ^e   Mullick, Alaka ^a,d   Whiteway, Malcolm ^a,b  

^a NATIONAL RESEARCH COUNCIL CANADA   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

^e UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE RIBOSYLATION FACTOR; BREFELDIN A; CALCINEURIN; CASPOFUNGIN; CYCLOSPORIN A; FLUCONAZOLE; KETOCONAZOLE; MICONAZOLE; STEROL; TACROLIMUS; ANTIFUNGAL AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; ASPERGILLUS FUMIGATUS; CANDIDA ALBICANS; CONTROLLED STUDY; DRUG POTENTIATION; DRUG TOLERANCE; FUNGAL GENE; FUNGAL GENETICS; FUNGAL GENOME; FUNGAL VIRULENCE; FUNGICIDAL ACTIVITY; FUNGUS MUTANT; GENE DELETION; GENETIC CODE; GENETIC SCREENING; INVASIVE CANDIDIASIS; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; SACCHAROMYCES CEREVISIAE; ANIMAL; ANTIFUNGAL RESISTANCE; DNA MICROARRAY; DRUG COMBINATION; DRUG EFFECT; GENE EXPRESSION; GENETICS; METABOLISM; PATHOGENICITY; TWO HYBRID SYSTEM; VIRULENCE;

ASPERGILLUS FUMIGATUS; CANDIDA; CANDIDA ALBICANS; MUS; SACCHAROMYCES CEREVISIAE;

ADP-RIBOSYLATION FACTORS; ANIMALS; ANTIFUNGAL AGENTS; BREFELDIN A; CANDIDA ALBICANS; DRUG RESISTANCE, FUNGAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FLUCONAZOLE; GENE EXPRESSION; MICE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; TWO-HYBRID SYSTEM TECHNIQUES; VIRULENCE;

EID: 77649256078     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1000753     Document Type: Article

References (104)

1. Nucci M, Marr KA (2005) Emerging fungal diseases. Clin Infect Dis 41: 521-526.
2. Pappas PG, Kauffman CA, Andes D, Benjamin DK Jr, Calandra TF, et al. (2009) Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 48: 503-535.
3. Pfaller MA, Diekema DJ (2007) Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 20: 133-163.
4. Wilson LS, Reyes CM, Stolpman M, Speckman J, Allen K, et al. (2002) The direct cost and incidence of systemic fungal infections. Value Health 5: 26-34.
5. Shao PL, Huang LM, Hsueh PR (2007) Recent advances and challenges in the treatment of invasive fungal infections. Int J Antimicrob Agents 30: 487-495.
6. Richardson M, Lass-Florl C (2008) Changing epidemiology of systemic fungal infections. Clin Microbiol Infect 14 Suppl 4: 5-24.
7. Pfaller Michael A, Pappas Peter G, Wingard John R (2006) Invasive Fungal Pathogens: Current Epidemiological Trends. Clinical Infectious Diseases 43: S3-S14.
8. Leroy O, Gangneux JP, Montravers P, Mira JP, Gouin F, et al. (2009) Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006). Crit Care Med 37: 1612-1618.
9. Pfaller MA, Diekema DJ (2004) Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus. J Clin Microbiol 42: 4419-4431.
10. Cowen L (2008) The evolution of fungal drug resistance: modulating the trajectory from genotype to phenotype. Nat Rev Micro 6: 187-198.
11. Chapman SW, Sullivan DC, Cleary JD (2008) In search of the holy grail of antifungal therapy. Trans Am Clin Climatol Assoc 119: 197-215; discussion 215-196.
12. Cowen LE, Steinbach WJ (2008) Stress, drugs, and evolution: the role of cellular signaling in fungal drug resistance. Eukaryot Cell 7: 747-764.
13. Cannon RD, Lamping E, Holmes AR, Niimi K, Baret PV, et al. (2009) Efflux-mediated antifungal drug resistance. Clin Microbiol Rev 22: 291-321, table of contents.
14. Traeder C, Kowoll S, Arasteh K (2008) Candida infection in HIV positive patients 1985-2007. Mycoses 51 Suppl 2: 58-61.
15. Pachl J, Svoboda P, Jacobs F, Vandewoude K, van der Hoven B, et al. (2006) A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis. Clin Infect Dis 42: 1404-1413.
16. Cowen LE, Singh SD, Kohler JR, Collins C, Zaas AK, et al. (2009) Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease. Proc Natl Acad Sci U S A 106: 2818-2823.
17. Singh SD, Robbins N, Zaas AK, Schell WA, Perfect JR, et al. (2009) Hsp90 governs echinocandin resistance in the pathogenic yeast Candida albicans via calcineurin. PLoS Pathog 5: e1000532. doi:10.1371/journal.ppat.1000532.
18. Cruz MC, Goldstein AL, Blankenship JR, Del Poeta M, Davis D, et al. (2002) Calcineurin is essential for survival during membrane stress in Candida albicans. EMBO J 21: 546-559.
19. Sanglard D, Ischer F, Marchetti O, Entenza J, Bille J (2003) Calcineurin A of Candida albicans: involvement in antifungal tolerance, cell morphogenesis and virulence. Mol Microbiol 48: 959-976.
20. Cowen LE, Lindquist S (2005) Hsp90 potentiates the rapid evolution of new traits: drug resistance in diverse fungi. Science 309: 2185-2189.
21. Marchetti O, Entenza JM, Sanglard D, Bille J, Glauser MP, et al. (2000) Fluconazole plus cyclosporine: a fungicidal combination effective against experimental endocarditis due to Candida albicans. Antimicrob Agents Chemother 44: 2932-2938.
22. Steinbach WJ, Reedy JL, Cramer RA Jr, Perfect JR, Heitman J (2007) Harnessing calcineurin as a novel anti-infective agent against invasive fungal infections. Nat Rev Microbiol 5: 418-430.
23. Lopez A, Parsons AB, Nislow C, Giaever G, Boone C (2008) Chemical-genetic approaches for exploring the mode of action of natural products. Prog Drug Res 66: 237, 239-271.
24. Hoon S, Smith AM, Wallace IM, Suresh S, Miranda M, et al. (2008) An integrated platform of genomic assays reveals small-molecule bioactivities. Nat Chem Biol 4: 498-506.
25. Ho CH, Magtanong L, Barker SL, Gresham D, Nishimura S, et al. (2009) A molecular barcoded yeast ORF library enables mode-of-action analysis of bioactive compounds. Nat Biotechnol 27: 369-377.
26. Butcher RA, Bhullar BS, Perlstein EO, Marsischky G, LaBaer J, et al. (2006) Microarray-based method for monitoring yeast overexpression strains reveals small-molecule targets in TOR pathway. Nat Chem Biol 2: 103-109.
27. Giaever G, Flaherty P, Kumm J, Proctor M, Nislow C, et al. (2004) Chemogenomic profiling: identifying the functional interactions of small molecules in yeast. Proc Natl Acad Sci U S A 101: 793-798.
28. Xu D, Jiang B, Ketela T, Lemieux S, Veillette K, et al. (2007) Genome-wide fitness test and mechanism-of-action studies of inhibitory compounds in Candida albicans. PLoS Pathog 3: e92. doi:10.1371/journal.ppat.0030092.
29. Jansen G, Lee AY, Epp E, Fredette A, Surprenant J, et al. (2009) Chemogenomic profiling predicts antifungal synergies. Mol Syst Biol 5: 338.
30. Uccelletti D, Farina F, Morlupi A, Palleschi C (1999) Mutants of Kluyveromyces lactis with altered protein glycosylation are affected in cell wall morphogenesis. Res Microbiol 150: 5-12.
31. Dean N (1995) Yeast glycosylation mutants are sensitive to aminoglycosides. Proc Natl Acad Sci U S A 92: 1287-1291.
32. Dean N, Poster JB (1996) Molecular and phenotypic analysis of the S. cerevisiae MNN10 gene identifies a family of related glycosyltransferases. Glycobiology 6: 73-81.
33. Morschhauser J (2002) The genetic basis of fluconazole resistance development in Candida albicans. Biochim Biophys Acta 1587: 240-248.
34. Kanafani ZA, Perfect JR (2008) Antimicrobial resistance: resistance to antifungal agents: mechanisms and clinical impact. Clin Infect Dis 46: 120-128.
35. Morschhauser J, Barker KS, Liu TT, Bla BWJ, Homayouni R, et al. (2007) The transcription factor Mrr1p controls expression of the MDR1 efflux pump and mediates multidrug resistance in Candida albicans. PLoS Pathog 3: e164. doi: 10.1371/journal.ppat.0030164.
36. Dunkel N, Liu TT, Barker KS, Homayouni R, Morschhauser J, et al. (2008) A gain-of-function mutation in the transcription factor Upc2p causes upregulation of ergosterol biosynthesis genes and increased fluconazole resistance in a clinical Candida albicans isolate. Eukaryot Cell 7: 1180-1190.
37. Poon PP, Wang X, Rotman M, Huber I, Cukierman E, et al. (1996) Saccharomyces cerevisiae Gcs1 is an ADP-ribosylation factor GTPase-activating protein. Proc Natl Acad Sci U S A 93: 10074-10077.
38. Moss J, Vaughan M (1998) Molecules in the ARF orbit. J Biol Chem 273: 21431-21434.
39. Poon PP, Cassel D, Spang A, Rotman M, Pick E, et al. (1999) Retrograde transport from the yeast Golgi is mediated by two ARF GAP proteins with overlapping function. EMBO J 18: 555-564.
40. Poon PP, Nothwehr SF, Singer RA, Johnston GC (2001) The Gcs1 and Age2 ArfGAP proteins provide overlapping essential function for transport from the yeast trans-Golgi network. J Cell Biol 155: 1239-1250.
41. Myers KR, Casanova JE (2008) Regulation of actin cytoskeleton dynamics by Arf-family GTPases. Trends Cell Biol 18: 184-192.
42. Gillingham AK, Munro S (2007) The small G proteins of the Arf family and their regulators. Annu Rev Cell Dev Biol 23: 579-611.
43. Singleton VL, Bohonos N, Ullstrup AJ (1958) Decumbin, a new compound from a species of Penicillium. Nature 181: 1072-1073.
44. Renault L, Guibert B, Cherfils J (2003) Structural snapshots of the mechanism and inhibition of a guanine nucleotide exchange factor. Nature 426: 525-530.
45. Cherfils J, Menetrey J, Mathieu M, Le Bras G, Robineau S, et al. (1998) Structure of the Sec7 domain of the Arf exchange factor ARNO. Nature 392: 101-105.
46. Goldberg J (1998) Structural basis for activation of ARF GTPase: mechanisms of guanine nucleotide exchange and GTP-myristoyl switching. Cell 95: 237-248.
47. Sata M, Moss J, Vaughan M (1999) Structural basis for the inhibitory effect of brefeldin A on guanine nucleotide-exchange proteins for ADP-ribosylation factors. Proc Natl Acad Sci U S A 96: 2752-2757.
48. Mossessova E, Corpina RA, Goldberg J (2003) Crystal structure of ARF1*Sec7 complexed with Brefeldin A and its implications for the guanine nucleotide exchange mechanism. Mol Cell 12: 1403-1411.
49. Znaidi S, De Deken X, Weber S, Rigby T, Nantel A, et al. (2007) The zinc cluster transcription factor Tac1p regulates PDR16 expression in Candida albicans. Mol Microbiol 66: 440-452.
50. Stevens DA, Espiritu M, Parmar R (2004) Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations. Antimicrob Agents Chemother 48: 3407-3411.
51. Fleischhacker M, Radecke C, Schulz B, Ruhnke M (2008) Paradoxical growth effects of the echinocandins caspofungin and micafungin, but not of anidulafungin, on clinical isolates of Candida albicans and C. dubliniensis. Eur J Clin Microbiol Infect Dis 27: 127-131.
52. Bruno VM, Kalachikov S, Subaran R, Nobile CJ, Kyratsous C, et al. (2006) Control of the C. albicans cell wall damage response by transcriptional regulator Cas5. PLoS Pathog 2: e21. doi:10.1371/journal.ppat.0020021.
53. Karababa M, Valentino E, Pardini G, Coste AT, Bille J, et al. (2006) CRZ1, a target of the calcineurin pathway in Candida albicans. Molecular Microbiology 59: 1429-1451.
54. Lepak A, Nett J, Lincoln L, Marchillo K, Andes D (2006) Time course of microbiologic outcome and gene expression in Candida albicans during and following in vitro and in vivo exposure to fluconazole. Antimicrob Agents Chemother 50: 1311-1319.
55. Sellam A, Tebbji F, Nantel A (2009) Role of Ndt80p in sterol metabolism regulation and azole resistance in Candida albicans. Eukaryot Cell 8: 1174-1183.
56. Liu TT, Lee RE, Barker KS, Wei L, Homayouni R, et al. (2005) Genome-wide expression profiling of the response to azole, polyene, echinocandin, and pyrimidine antifungal agents in Candida albicans. Antimicrob Agents Chemother 49: 2226-2236.
57. Whiteway M, Bachewich C (2007) Morphogenesis in Candida albicans. Annu Rev Microbiol 61: 529-553.
58. Mullick A, Elias M, Picard S, Bourget L, Jovcevski O, et al. (2004) Dysregulated inflammatory response to Candida albicans in a C5-deficient mouse strain. Infect Immun 72: 5868-5876.
59. Gauwerky K, Borelli C, Korting HC (2009) Targeting virulence: a new paradigm for antifungals. Drug Discov Today 14: 214-222.
60. Sellam A, Askew C, Epp E, Lavoie H, Whiteway M, et al. (2009) Genome-wide mapping of the coactivator Ada2p yields insight into the functional roles of SAGA/ADA complex in Candida albicans. Mol Biol Cell 20: 2389-2400.
61. Sanglard D, Ischer F, Parkinson T, Falconer D, Bille J (2003) Candida albicans mutations in the ergosterol biosynthetic pathway and resistance to several antifungal agents. Antimicrob Agents Chemother 47: 2404-2412.
62. Timmers HT, Tora L (2005) SAGA unveiled. Trends Biochem Sci 30: 7-10.
63. Znaidi S, Weber S, Al-Abdin OZ, Bomme P, Saidane S, et al. (2008) Genomewide location analysis of Candida albicans Upc2p, a regulator of sterol metabolism and azole drug resistance. Eukaryot Cell 7: 836-847.
64. Liu TT, Znaidi S, Barker KS, Xu L, Homayouni R, et al. (2007) Genome-wide expression and location analyses of the Candida albicans Tac1p regulon. Eukaryot Cell 6: 2122-2138.
65. Tuch BB, Li H, Johnson AD (2008) Evolution of eukaryotic transcription circuits. Science 319: 1797-1799.
66. Hogues H, Lavoie H, Sellam A, Mangos M, Roemer T, et al. (2008) Transcription factor substitution during the evolution of fungal ribosome regulation. Mol Cell 29: 552-562.
67. Askew C, Sellam A, Epp E, Hogues H, Mullick A, et al. (2009) Transcriptional Regulation of Carbohydrate Metabolism in the Human Pathogen Candida albicans. PLoS Pathog 5: e1000612. doi:10.1371/journal.ppat.1000612.
68. Jia N, Arthington-Skaggs B, Lee W, Pierson CA, Lees ND, et al. (2002) Candida albicans sterol C-14 reductase, encoded by the ERG24 gene, as a potential antifungal target site. Antimicrob Agents Chemother 46: 947-957.
69. Sanglard D, Coste A, Ferrari S (2009) Antifungal drug resistance mechanisms in fungal pathogens from the perspective of transcriptional gene regulation. FEMS Yeast Res 9: 1029-1050.
70. Cowen L, Steinbach W (2008) Stress, Drugs, and Evolution: the Role of Cellular Signaling in Fungal Drug Resistance. Eukaryotic Cell 7: 747-764.
71. d'Enfert C (2009) Hidden killers: persistence of opportunistic fungal pathogens in the human host. Curr Opin Microbiol 12: 358-364.
72. Bruning A, Ishikawa T, Kneusel RE, Matern U, Lottspeich F, et al. (1992) Brefeldin A binds to glutathione S-transferase and is secreted as glutathione and cysteine conjugates by Chinese hamster ovary cells. J Biol Chem 267: 7726-7732.
73. Fox BM, Vroman JA, Fanwick PE, Cushman M (2001) Preparation and evaluation of sulfide derivatives of the antibiotic brefeldin a as potential prodrug candidates with enhanced aqueous solubilities. J Med Chem 44: 3915-3924.
74. Anadu NO, Davisson VJ, Cushman M (2006) Synthesis and anticancer activity of brefeldin A ester derivatives. J Med Chem 49: 3897-3905.
75. Shao RG, Shimizu T, Pommier Y (1996) Brefeldin A is a potent inducer of apoptosis in human cancer cells independently of p53. Exp Cell Res 227: 190-196.
76. Zhu J-W, Hori H, Nojiri H, Tsukuda T, Taira Z (1997) Synthesis and activity of brefeldin a analogs as inducers of cancer cell differentiation and apoptosis. Bioorganic & Medicinal Chemistry Letters 7: 139-144.
77. Zhu JW, Nagasawa H, Nagura F, Mohamad SB, Uto Y, et al. (2000) Elucidation of strict structural requirements of brefeldin A as an inducer of differentiation and apoptosis. Bioorg Med Chem 8: 455-463.
78. Nojiri H, Manya H, Isono H, Yamana H, Nojima S (1999) Induction of terminal differentiation and apoptosis in human colonic carcinoma cells by brefeldin A, a drug affecting ganglioside biosynthesis. FEBS Lett 453: 140-144.
79. Guo H, Tittle TV, Allen H, Maziarz RT (1998) Brefeldin A-mediated apoptosis requires the activation of caspases and is inhibited by Bcl-2. Exp Cell Res 245: 57-68.
80. Hacki J, Egger L, Monney L, Conus S, Rosse T, et al. (2000) Apoptotic crosstalk between the endoplasmic reticulum and mitochondria controlled by Bcl-2. Oncogene 19: 2286-2295.
81. Sahai E, Marshall CJ (2002) RHO-GTPases and cancer. Nat Rev Cancer 2: 133-142.
82. Downward J (2003) Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 3: 11-22.
83. Sabe H, Onodera Y, Mazaki Y, Hashimoto S (2006) ArfGAP family proteins in cell adhesion, migration and tumor invasion. Curr Opin Cell Biol 18: 558-564.
84. Cherfils J, Chardin P (1999) GEFs: structural basis for their activation of small GTP-binding proteins. Trends Biochem Sci 24: 306-311.
85. Amor JC, Horton JR, Zhu X, Wang Y, Sullards C, et al. (2001) Structures of yeast ARF2 and ARL1: distinct roles for the N terminus in the structure and function of ARF family GTPases. J Biol Chem 276: 42477-42484.
86. Marchetti O, Moreillon P, Glauser MP, Bille J, Sanglard D (2000) Potent synergism of the combination of fluconazole and cyclosporine in Candida albicans. Antimicrob Agents Chemother 44: 2373-2381.
87. Bader T, Bodendorfer B, Schroppel K, Morschhauser J (2003) Calcineurin is essential for virulence in Candida albicans. Infect Immun 71: 5344-5354.
88. Blankenship JR, Heitman J (2005) Calcineurin is required for Candida albicans to survive calcium stress in serum. Infect Immun 73: 5767-5774.
89. (SGD project. The Saccharomyces Genome Database, www.yeastgenome.org (as of October 2009)).
90. Davis DA, Bruno VM, Loza L, Filler SG, Mitchell AP (2002) Candida albicans Mds3p, a conserved regulator of pH responses and virulence identified through insertional mutagenesis. Genetics 162: 1573-1581.
91. Arnaud MB, Costanzo MC, Skrzypek MS, Shah P, Binkley G, et al. (2007) Sequence resources at the Candida Genome Database. Nucleic Acids Res 35: D452-456.
92. Gola S, Martin R, Walther A, Dünkler A, Wendland J (2003) New modules for PCR-based gene targeting in Candida albicans: rapid and efficient gene targeting using 100 bp of flanking homology region. Yeast 20: 1339-1347.
93. Chen DC, Yang BC, Kuo TT (1992) One-step transformation of yeast in stationary phase. Curr Genet 21: 83-84.
94. Walther A, Wendland J (2008) PCR-based gene targeting in Candida albicans. Nat Protoc 3: 1414-1421.
95. Bouchonville K, Forche A, Tang KE, Selmecki A, Berman J (2009) Aneuploid chromosomes are highly unstable during DNA transformation of Candida albicans. Eukaryot Cell 8: 1554-1566.
96. Arbour M, Epp E, Hogues H, Sellam A, Lacroix C, et al. (2009) Widespread occurrence of chromosomal aneuploidy following the routine production of Candida albicans mutants. FEMS Yeast Res.
97. Reuss O, Vik A, Kolter R, Morschhäuser J (2004) The SAT1 flipper, an optimized tool for gene disruption in Candida albicans. Gene 341: 119-127.
98. Noble SM, Johnson AD (2005) Strains and Strategies for Large-Scale Gene Deletion Studies of the Diploid Human Fungal Pathogen Candida albicans. Eukaryotic Cell.
99. NCCLS. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard-Second Edition. NCCLS document M27-A2 [ISBN 1-56238-469-4]. NCCLS, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2002.
100. Loewe S (1953) The problem of synergism and antagonism of combined drugs. Arzneimittelforschung 3: 285-290.
101. Barchiesi F, Di Francesco LF, Compagnucci P, Arzeni D, Giacometti A, et al. (1998) In-vitro interaction of terbinafine with amphotericin B, fluconazole and itraconazole against clinical isolates of Candida albicans. J Antimicrob Chemother 41: 59-65.
102. NCCLS. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi; Approved Standard. NCCLS document M38-A [ISBN 1-56238-470-8]. NCCLS, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2002.
103. Kohrer K, Domdey H (1991) Preparation of high molecular weight RNA. Methods Enzymol 194: 398-405.
104. Nantel A, Rigby T, Hogues H, Whiteway M (2006) Microarrays for studying pathogenicity in Candida albicans; Kavanaugh KH, ed. New Jersey: Wiley Press.